Format

Send to

Choose Destination
Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Author information

1
Departments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
2
Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
3
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
4
Breast Cancer Program, Vanderbilt University Medical Center, Nashville, Tennessee.
5
Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
6
Department of Oncology and Hematology, Hospital ClinicoUniversitario, INCLIVA Biomedical Research Institute, University of Valencia, CIBERONC, Valencia, Spain.
7
Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain.
8
Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.
9
CESP, Faculté de Médecine, Université Paris Sud, Faculté de Médecine UVSQ, INSERM, Université Paris Saclay, Villejuif, France.
10
Department of Medical Oncology, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.
11
Departments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. carlos.arteaga@utsouthwestern.edu.
12
Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Abstract

Purpose: This study aimed to identify biomarkers of resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancers treated with prolonged neoadjuvant letrozole.Experimental Design: We performed targeted DNA and RNA sequencing in 68 ER+ breast cancers from patients treated with preoperative letrozole (median, 7 months).Results: Twenty-four tumors (35%) exhibited a PEPI score ≥4 and/or recurred after a median of 58 months and were considered endocrine resistant. Integration of the 47 most upregulated genes (log FC > 1, FDR < 0.03) in letrozole-resistant tumors with transcription-binding data showed significant overlap with 20 E2F4-regulated genes (P = 2.56E-15). In patients treated with the CDK4/6 inhibitor palbociclib before surgery, treatment significantly decreased expression of 24 of the 47 most upregulated genes in letrozole-resistant tumors, including 18 of the 20 E2F4 target genes. In long-term estrogen-deprived ER+ breast cancer cells, palbociclib also downregulated all 20 E2F4 target genes and P-RB levels, whereas the ER downregulator fulvestrant or paclitaxel only partially suppressed expression of this set of genes and had no effect on P-RB. Finally, an E2F4 activation signature was strongly associated with resistance to aromatase inhibitors in the ACOSOG Z1031B neoadjuvant trial and with an increased risk of relapse in adjuvant-treated ER+ tumors in METABRIC.Conclusions: In tumors resistant to prolonged neoadjuvant letrozole, we identified a gene expression signature of E2F4 target activation. CDK4/6 inhibition suppressed E2F4 target gene expression in estrogen-deprived ER+ breast cancer cells and in patients' ER+ tumors, suggesting a potential benefit of adjuvant CDK4/6 inhibitors in patients with ER+ breast cancer who fail to respond to preoperative estrogen deprivation. Clin Cancer Res; 24(11); 2517-29. ©2018 AACR.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center